Parkinson's disease: From genetics to treatments

Cell Transplantation

Volumn 22, Issue 4, 2013, Pages 639-652

  Fan, Hueng Chuen ^a   Chen, Shyi Jou ^a   Harn, Horng Jyh ^b   Lin, Shinn Zong ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

synuclein; ATPase type 13A2 (ATP13A2); Cellular transplantation; DJ1; Familial parkinson's disease (PD); Genetics; Leucine rich repeat kinase (LRRK2); Parkin; PTEN induced kinase 1 (PINK1)

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA SYNUCLEIN; ATPASE TYPE 13A2; BUTYRIC ACID; CARBIDOPA; DJ 1 PROTEIN; ENZYME; HISTONE DEACETYLASE INHIBITOR; LEUCINE RICH REPEAT KINASE 2; MONOAMINE OXIDASE B INHIBITOR; PARKIN; PTEN INDUCED KINASE 1; SIRTUIN 2 INHIBITOR; UNCLASSIFIED DRUG; VORINOSTAT;

AKINESIA; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; BRADYKINESIA; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DYSARTHRIA; EMBRYONIC STEM CELL; GENE; GENETIC SCREENING; GENETICS; GLOBUS PALLIDUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMIPARESIS; HUMAN; HYPERKINESIA; HYPOKINESIA; LEWY BODY; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVE CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; PATHOGENESIS; PLURIPOTENT STEM CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; RIGIDITY; STEM CELL; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; THALAMOTOMY; TISSUE INJURY; TREMOR; UMBILICAL CORD BLOOD;

ANIMALS; HUMANS; LEWY BODIES; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; PREVALENCE; STEM CELL TRANSPLANTATION;

EID: 84876501668     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X655082     Document Type: Review

References (166)

1. Abeliovich, A.; Schmitz, Y.; Farinas, I.; Choi-Lundberg, D.; Ho, W. H.; Castillo, P. E.; Shinsky, N.; Verdugo, J. M.; Armanini, M.; Ryan, A.; Hynes, M.; Phillips, H.; Sulzer, D.; Rosenthal, A. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239-252; 2000.
2. Aharon-Peretz, J.; Rosenbaum, H.; Gershoni-Baruch, R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 351(19):1972-1977; 2004.96
3. Anderson, J. P.; Walker, D. E.; Goldstein, J. M.; de Laat, R.; Banducci, K.; Caccavello, R. J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; Diep, L.; Keim, P. S.; Shen, X.; Chataway, T.; Schlossmacher, M. G.; Seubert, P.; Schenk, D.; Sinha, S.; Gai, W. P.; Chilcote, T. J. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281(40):29739-29752; 2006.
4. Banisadr, G.; Skrzydelski, D.; Kitabgi, P.; Rostene, W.; Parsadaniantz, S. M. Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: Constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur. J. Neurosci. 18(6):1593-1606; 2003.
5. Barberi, T.; Klivenyi, P.; Calingasan, N. Y.; Lee, H.; Kawamata, H.; Loonam, K.; Perrier, A. L.; Bruses, J.; Rubio, M. E.; Topf, N.; Tabar, V.; Harrison, N. L.; Beal, M. F.; Moore, M. A.; Studer, L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat. Biotechnol. 21(10):1200-1207; 2003.
6. Belarbi, S.; Hecham, N.; Lesage, S.; Kediha, M. I.; Smail, N.; Benhassine, T.; Ysmail-Dahlouk, F.; Lohman, E.; Benhabyles, B.; Hamadouche, T.; Assami, S.; Brice, A.; Tazir, M. LRRK2 G2019S mutation in Parkinson's disease: A neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism Relat. Disord. 16(10):676-679; 2010.
7. Bender, A.; Krishnan, K. J.; Morris, C. M.; Taylor, G. A.; Reeve, A. K.; Perry, R. H.; Jaros, E.; Hersheson, J. S.; Betts, J.; Klopstock, T.; Taylor, R. W.; Turnbull, D. M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38(5):515-517; 2006.
8. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Jellinger, K.; Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20(4):415-455; 1973.
9. Bjorklund, A.; Lindvall, O. Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 3(6):537-544; 2000.
10. Bjorklund, A.; Stenevi, U. Regeneration of monoaminergic and cholinergic neurons in the mammalian central nervous system. Physiol. Rev. 59(1):62-100; 1979.
11. Bjorklund, A.; Stenevi, U.; Svendgaard, N. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature 262(5571):787-790; 1976.
12. Bonifati, V.; Rohe, C. F.; Breedveld, G. J.; Fabrizio, E.; De Mari, M.; Tassorelli, C.; Tavella, A.; Marconi, R.; Nicholl, D. J.; Chien, H. F.; Fincati, E.; Abbruzzese, G.; Marini, P.; De Gaetano, A.; Horstink, M. W.; Maat-Kievit, J. A.; Sampaio, C.; Antonini, A.; Stocchi, F.; Montagna, P.; Toni, V.; Guidi, M.; Dalla Libera, A.; Tinazzi, M.; De Pandis, F.; Fabbrini, G.; Goldwurm, S.; de Klein, A.; Barbosa, E.; Lopiano, L.; Martignoni, E.; Lamberti, P.; Vanacore, N.; Meco, G.; Oostra, B. A. Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. Neurology 65(1):87-95; 2005.
13. Boudreaux, D. A.; Maiti, T. K.; Davies, C. W.; Das, C. Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc. Natl. Acad. Sci. USA 107(20):9117-9122; 2010.
14. Brown, D. R. Interactions between metals and α-synuclein- function or artefact? FEBS J. 274(15):3766-3774; 2007.
15. Brown, D. R. Metal binding to α-synuclein peptides and its contribution to toxicity. Biochem. Biophys. Res. Commun. 380(2):377-381; 2009.
16. Brundin, P.; Karlsson, J.; Emgard, M.; Schierle, G. S.; Hansson, O.; Petersen, A.; Castilho, R. F. Improving the survival of grafted dopaminergic neurons: A review over current approaches. Cell Transplant. 9(2):179-195; 2000.
17. Chen, J.; Zhang, Z. G.; Li, Y.; Wang, L.; Xu, Y. X.; Gautam, S. C.; Lu, M.; Zhu, Z.; Chopp, M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ. Res. 92(6):692-699; 2003.
18. Chen, R. C.; Chang, S. F.; Su, C. L.; Chen, T. H.; Yen, M. F.; Wu, H. M.; Chen, Z. Y.; Liou, H. H. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan. Neurology 57(9):1679-1686; 2001.
19. Cho, S. R.; Yang, M. S.; Yim, S. H.; Park, J. H.; Lee, J. E.; Eom, Y. W.; Jang, I. K.; Kim, H. E.; Park, J. S.; Kim, H. O.; Lee, B. H.; Park, C. I.; Kim, Y. J. Neurally induced umbilical cord blood cells modestly repair injured spinal cords. Neuroreport 19(13):1259-1263; 2008.
20. Christophersen, N. S.; Meijer, X.; Jorgensen, J. R.; Englund, U.; Gronborg, M.; Seiger, A.; Brundin, P.; Wahlberg, L. U. Induction of dopaminergic neurons from growth factor expanded neural stem/progenitor cell cultures derived from human first trimester forebrain. Brain Res. Bull. 70(4-6): 457-466; 2006.
21. Chu, Y.; Kordower, J. H. Lewy body pathology in fetal grafts. Ann. N. Y. Acad. Sci. 1184:55-67; 2010.
22. Clayton, D. F.; George, J. M. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegene- ration and disease. Trends Neurosci. 21(6):249-254; 1998.
23. Cole, N. B.; Dieuliis, D.; Leo, P.; Mitchell, D. C.; Nussbaum, R. L. Mitochondrial translocation of α-synuclein is promoted by intracellular acidification. Exp. Cell Res. 314(10):2076-2089; 2008.
24. Cooper, A. A.; Gitler, A. D.; Cashikar, A.; Haynes, C. M.; Hill, K. J.; Bhullar, B.; Liu, K.; Xu, K.; Strathearn, K. E.; Liu, F.; Cao, S.; Caldwell, K. A.; Caldwell, G. A.; Marsischky, G.; Kolodner, R. D.; Labaer, J.; Rochet, J. C.; Bonini, N. M.; Lindquist, S. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313(5785):324-328; 2006.
25. Darios, F.; Corti, O.; Lucking, C. B.; Hampe, C.; Muriel, M. P.; Abbas, N.; Gu, W. J.; Hirsch, E. C.; Rooney, T.; Ruberg, M.; Brice, A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12(5):517-526; 2003.
26. Dawson, T. M.; Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302(5646):819-822; 2003.
27. de Lau, L. M.; Breteler, M. M. Epidemiology of Parkinson's disease. Lancet Neurol. 5(6):525-535; 2006.
28. Deng, H.; Jankovic, J.; Guo, Y.; Xie, W.; Le, W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys. Res. Commun. 337(4):1133-1138; 2005.
29. Devi, L.; Raghavendran, V.; Prabhu, B. M.; Avadhani, N. G.; Anandatheerthavarada, H. K. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283(14):9089-9100; 2008.
30. Dickson, D. W.; Feany, M. B.; Yen, S. H.; Mattiace, L. A.; Davies, P. Cytoskeletal pathology in non-Alzheimer degenerative dementia: New lesions in diffuse Lewy body disease, Pick's disease, and corticobasal degeneration. J. Neural Transm. Suppl 47:31-46; 1996.
31. Di Fonzo, A.; Chien, H. F.; Socal, M.; Giraudo, S.; Tassorelli, C.; Iliceto, G.; Fabbrini, G.; Marconi, R.; Fincati, E.; Abbruzzese, G.; Marini, P.; Squitieri, F.; Horstink, M. W.; Montagna, P.; Libera, A. D.; Stocchi, F.; Goldwurm, S.; Ferreira, J. J.; Meco, G.; Martignoni, E.; Lopiano, L.; Jardim, L. B.; Oostra, B. A.; Barbosa, E. R.; Bonifati, V. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68(19):1557-1562; 2007.
32. Dimos, J. T.; Rodolfa, K. T.; Niakan, K. K.; Weisenthal, L. M.; Mitsumoto, H.; Chung, W.; Croft, G. F.; Saphier, G.; Leibel, R.; Goland, R.; Wichterle, H.; Henderson, C. E.; Eggan, K. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893):1218-1221; 2008.
33. Divinski, I.; Mittelman, L.; Gozes, I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem. 279(27):28531-28538; 2004.
34. Dunnett, S. B.; Bjorklund, A.; Lindvall, O. Cell therapy in Parkinson's disease-stop or go? Nat. Rev. Neurosci. 2(5):365-369; 2001.
35. Ebert, A. D.; Yu, J.; Rose, Jr., F. F.; Mattis, V. B.; Lorson, C. L.; Thomson, J. A.; Svendsen, C. N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 457(7227):277-280; 2009.
36. Emgard, M.; Hallin, U.; Karlsson, J.; Bahr, B. A.; Brundin, P.; Blomgren, K. Both apoptosis and necrosis occur early after intracerebral grafting of ventral mesencephalic tissue: A role for protease activation. J. Neurochem. 86(5):1223-1232; 2003.
37. Engelender, S.; Wanner, T.; Kleiderlein, J. J.; Wakabayashi, K.; Tsuji, S.; Takahashi, H.; Ashworth, R.; Margolis, R. L.; Ross, C. A. Organization of the human synphilin-1 gene, a candidate for Parkinson's disease. Mamm. Genome 11(9):763-766; 2000.
38. Felts, S. J.; Owen, B. A.; Nguyen, P.; Trepel, J.; Donner, D. B.; Toft, D. O. The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 275(5):3305-3312; 2000.
39. Fernandez, C. O.; Hoyer, W.; Zweckstetter, M.; Jares- Erijman, E. A.; Subramaniam, V.; Griesinger, C.; Jovin, T. M. NMR of α-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J. 23(10):2039-2046; 2004.
40. Fleming, S. M.; Mulligan, C. K.; Richter, F.; Mortazavi, F.; Lemesre, V.; Frias, C.; Zhu, C.; Stewart, A.; Gozes, I.; Morimoto, B.; Chesselet, M. F. A pilot trial of the microtubule- interacting peptide (NAP) in mice overexpressing α-synuclein shows improvement in motor function and reduction of α-synuclein inclusions. Mol. Cell. Neurosci. 46(3):597-606; 2011.
41. Forno, L. S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55(3):259-272; 1996.
42. Fuchs, J.; Nilsson, C.; Kachergus, J.; Munz, M.; Larsson, E. M.; Schule, B.; Langston, J. W.; Middleton, F. A.; Ross, O. A.; Hulihan, M.; Gasser, T.; Farrer, M. J. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68(12):916-922; 2007.
43. Galter, D.; Westerlund, M.; Carmine, A.; Lindqvist, E.; Sydow, O.; Olson, L. LRRK2 expression linked to dopamineinnervated areas. Ann. Neurol. 59(4):714-719; 2006.
44. George, J. M.; Jin, H.; Woods, W. S.; Clayton, D. F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15(2):361-372; 1995.
45. Georgievska, B.; Kirik, D.; Rosenblad, C.; Lundberg, C.; Bjorklund, A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13(1):75-82; 2002.
46. German, D. C.; Manaye, K. F.; White, III. C. L.; Woodward, D. J.; McIntire, D. D.; Smith, W. K.; Kalaria, R. N.; Mann, D. M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32(5):667-676; 1992.
47. Gilks, W. P.; bou-Sleiman, P. M.; Gandhi, S.; Jain, S.; Singleton, A.; Lees, A. J.; Shaw, K.; Bhatia, K. P.; Bonifati, V.; Quinn, N. P.; Lynch, J.; Healy, D. G.; Holton, J. L.; Revesz, T.; Wood, N. W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365(9457):415-416; 2005.
48. Gitler, A. D.; Chesi, A.; Geddie, M. L.; Strathearn, K. E.; Hamamichi, S.; Hill, K. J.; Caldwell, K. A.; Caldwell, G. A.; Cooper, A. A.; Rochet, J. C.; Lindquist, S. α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41(3):308-315; 2009.
49. Gozes, I.; Divinski, I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J. Alzheimers Dis. 6(6 Suppl):S37-S41; 2004.
50. Greene, J. C.; Whitworth, A. J.; Andrews, L. A.; Parker, T. J.; Pallanck, L. J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14(6):799-811; 2005.
51. Greene, J. C.; Whitworth, A. J.; Kuo, I.; Andrews, L. A.; Feany, M. B.; Pallanck, L. J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 100(7):4078-4083; 2003.
52. Groiss, S. J.; Wojtecki, L.; Sudmeyer, M.; Schnitzler, A. Deep brain stimulation in Parkinson's disease. Ther. Adv. Neurol. Disord. 2(6):20-28; 2009.
53. Hellmann, M. A.; Panet, H.; Barhum, Y.; Melamed, E.; Offen, D. Increased survival and migration of engrafted mesen-chymal bone marrow stem cells in 6-hydroxydopamine- lesioned rodents. Neurosci. Lett. 395(2):124-128; 2006.
54. Hirsch, E.; Graybiel, A. M.; Agid, Y. A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334(6180):345-348; 1988.
55. Hoffer, B.; Olson, L.; Seiger, A.; Bloom, F. Formation of a functional adrenergic input to intraocular cerebellar grafts: Ingrowth of inhibitory sympathetic fibers. J. Neurobiol. 6(6):565-585; 1975.
56. Hu, C. J.; Sung, S. M.; Liu, H.; Chang, J. G. No mutation of G209A in the α-synuclein gene in sporadic Parkinson's disease among Taiwan Chinese. Eur. Neurol. 41(2):85- 87; 1999.
57. Ibáñez, P.; Lesage, S.; Janin, S.; Lohmann, E.; Durif, F.; Destee, A.; Bonnet, A. M.; Brefel-Courbon, C.; Heath, S.; Zelenika, D.; Agid, Y.; Durr, A.; Brice, A. α-Synuclein gene rearrangements in dominantly inherited parkinsonism: Frequency, phenotype, and mechanisms. Arch. Neurol. 66(1):102-108; 2009.
58. Ibáñez, P.; Lesage, S.; Lohmann, E.; Thobois, S.; De Michele, G.; Borg, M.; Agid, Y.; Durr, A.; Brice, A. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129(Pt 3): 686-694; 2006.
59. Imai, Y.; Gehrke, S.; Wang, H. Q.; Takahashi, R.; Hasegawa, K.; Oota, E.; Lu, B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27(18):2432-2443; 2008.
60. Inglis, K. J.; Chereau, D.; Brigham, E. F.; Chiou, S. S.; Schobel, S.; Frigon, N. L.; Yu, M.; Caccavello, R. J.; Nelson, S.; Motter, R.; Wright, S.; Chian, D.; Santiago, P.; Soriano, F.; Ramos, C.; Powell, K.; Goldstein, J. M.; Babcock, M.; Yednock, T.; Bard, F.; Basi, G. S.; Sham, H.; Chilcote, T. J.; McConlogue, L.; Griswold-Prenner, I.; Anderson, J. P. Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284(5):2598-2602; 2009.
61. Jellinger, K. A. More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains. Acta Neuropathol. 114(3):299-303; 2007.
62. Jellinger, K. A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14(3):153-197; 1991.
63. Jensen, P. H.; Hager, H.; Nielsen, M. S.; Hojrup, P.; Gliemann, J.; Jakes, R. α-Synuclein binds to Tau and stimulates the protein kinase α-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274(36):25481-25489; 1999.
64. Kamp, F.; Exner, N.; Lutz, A. K.; Wender, N.; Hegermann, J.; Brunner, B.; Nuscher, B.; Bartels, T.; Giese, A.; Beyer, K.; Eimer, S.; Winklhofer, K. F.; Haass, C. Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29(20):3571-3589; 2010.
65. Kim, D. W. Efficient induction of dopaminergic neurons from embryonic stem cells for application to Parkinson's disease. Yonsei Med. J. 45 Suppl:23-27; 2004.
66. Kim, M.; Jung, W.; Lee, I. H.; Bhak, G.; Paik, S. R.; Hahn, J. S. Impairment of microtubule system increases asynuclein aggregation and toxicity. Biochem. Biophys. Res. Commun. 365(4):628-635; 2008.
67. Kinumi, T.; Kimata, J.; Taira, T.; Ariga, H.; Niki, E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 317(3):722-728; 2004.
68. Kirik, D.; Rosenblad, C.; Burger, C.; Lundberg, C.; Johansen, T. E.; Muzyczka, N.; Mandel, R. J.; Bjorklund, A. Parkinson-like neurodegeneration induced by targeted overexpression of α-synuclein in the nigrostriatal system. J. Neurosci. 22(7):2780-2791; 2002.
69. Klein, C.; Lohmann-Hedrich, K.; Rogaeva, E.; Schlossmacher, M. G.; Lang, A. E. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 6(7):652-662; 2007.
70. Klein, C.; Westenberger, A. Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2(1):a008888; 2012.
71. Kontopoulos, E.; Parvin, J. D.; Feany, M. B. α-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15(20):3012-3023; 2006.
72. Kordower, J. H.; Chu, Y.; Hauser, R. A.; Freeman, T. B.; Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14(5):504-506; 2008.
73. Krack, P.; Vercueil, L. Review of the functional surgical treatment of dystonia. Eur. J. Neurol. 8(5):389-399; 2001.
74. Kraytsberg, Y.; Kudryavtseva, E.; McKee, A. C.; Geula, C.; Kowall, N. W.; Khrapko, K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38(5): 518-520; 2006.
75. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J. T.; Schols, L.; Riess, O. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18(2):106-108; 1998.
76. Lautier, C.; Goldwurm, S.; Durr, A.; Giovannone, B.; Tsiaras, W. G.; Pezzoli, G.; Brice, A.; Smith, R. J. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am. J. Hum. Genet. 82(4): 822-833; 2008.
77. Le, W.; Conneely, O. M.; He, Y.; Jankovic, J.; Appel, S. H. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73(5):2218-2221; 1999.
78. Le, W. D.; Xu, P.; Jankovic, J.; Jiang, H.; Appel, S. H.; Smith, R. G.; Vassilatis, D. K. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 33(1):85-89; 2003.
79. Lee, H. J.; Khoshaghideh, F.; Lee, S.; Lee, S. J. Impairment of microtubule-dependent trafficking by overexpression of α-synuclein. Eur. J. Neurosci. 24(11):3153-3162; 2006.
80. Leroy, E.; Boyer, R.; Auburger, G.; Leube, B.; Ulm, G.; Mezey, E.; Harta, G.; Brownstein, M. J.; Jonnalagada, S.; Chernova, T.; Dehejia, A.; Lavedan, C.; Gasser, T.; Steinbach, P. J.; Wilkinson, K. D.; Polymeropoulos, M. H. The ubiquitin pathway in Parkinson's disease. Nature 395 (6701):451-452; 1998.
81. Lesage, S.; Durr, A.; Tazir, M.; Lohmann, E.; Leutenegger, A. L.; Janin, S.; Pollak, P.; Brice, A. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354(4):422-423; 2006.
82. Lesage, S.; Patin, E.; Condroyer, C.; Leutenegger, A. L.; Lohmann, E.; Giladi, N.; Bar-Shira, A.; Belarbi, S.; Hecham, N.; Pollak, P.; Ouvrard-Hernandez, A. M.; Bardien, S.; Carr, J.; Benhassine, T.; Tomiyama, H.; Pirkevi, C.; Hamadouche, T.; Cazeneuve, C.; Basak, A. N.; Hattori, N.; Durr, A.; Tazir, M.; Orr-Urtreger, A.; Quintana-Murci, L.; Brice, A. Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum. Mol. Genet. 19(10):1998-2004; 2010.
83. Levin, J.; Giese, A.; Boetzel, K.; Israel, L.; Hogen, T.; Nubling, G.; Kretzschmar, H.; Lorenzl, S. Increased asynuclein aggregation following limited cleavage by certain matrix metalloproteinases. Exp. Neurol. 215(1):201-208; 2009.
84. Li, Y.; Chen, J.; Wang, L.; Zhang, L.; Lu, M.; Chopp, M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci. Lett. 316(2): 67-70; 2001.
85. Lim, J. J.; Jang, J. B.; Kim, J. Y.; Moon, S. H.; Lee, C. N.; Lee, K. J. Human umbilical cord blood mononuclear cell transplantation in rats with intrinsic sphincter deficiency. J. Korean Med Sci. 25(5):663-670; 2010.
86. Lin, J. J.; Yueh, K. C.; Chang, D. C.; Lin, S. Z. Absence of G209A and G88C mutations in the α-synuclein gene of Parkinson's disease in a Chinese population. Eur. Neurol. 42(4):217-220; 1999.
87. Lindvall, O.; Hagell, P. Clinical observations after neural transplantation in Parkinson's disease. Prog. Brain Res. 127:299-320; 2000.
88. Louis, S. A.; Reynolds, B. A. Generation and differentiation of neurospheres from murine embryonic day 14 central nervous system tissue. Methods Mol. Biol. 290:265-280; 2005.
89. Lu, L.; Zhao, C.; Liu, Y.; Sun, X.; Duan, C.; Ji, M.; Zhao, H.; Xu, Q.; Yang, H. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Res. Brain Res. Protoc. 15(1):46-51; 2005.
90. Lucking, C. B.; Durr, A.; Bonifati, V.; Vaughan, J.; De Michele, G.; Gasser, T.; Harhangi, B. S.; Meco, G.; Denefle, P.; Wood, N. W.; Agid, Y.; Brice, A. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342(21):1560-1567; 2000.
91. Machiya, Y.; Hara, S.; Arawaka, S.; Fukushima, S.; Sato, H.; Sakamoto, M.; Koyama, S.; Kato, T. Phosphorylated α-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J. Biol. Chem. 285(52):40732-40744; 2010.
92. Mareschi, K.; Novara, M.; Rustichelli, D.; Ferrero, I.; Guido, D.; Carbone, E.; Medico, E.; Madon, E.; Vercelli, A.; Fagioli, F. Neural differentiation of human mesenchymal stem cells: Evidence for expression of neural markers and eag K+ channel types. Exp. Hematol. 34(11):1563-1572; 2006.
93. Martinat, C.; Bacci, J. J.; Leete, T.; Kim, J.; Vanti, W. B.; Newman, A. H.; Cha, J. H.; Gether, U.; Wang, H.; Abeliovich, A. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc. Natl. Acad. Sci. USA 103(8):2874-2879; 2006.
94. Marx, F. P.; Holzmann, C.; Strauss, K. M.; Li, L.; Eberhardt, O.; Gerhardt, E.; Cookson, M. R.; Hernandez, D.; Farrer, M. J.; Kachergus, J.; Engelender, S.; Ross, C. A.; Berger, K.; Schols, L.; Schulz, J. B.; Riess, O.; Kruger, R. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum. Mol. Genet. 12(11):1223-1231; 2003.
95. Masliah, E.; Rockenstein, E.; Veinbergs, I.; Mallory, M.; Hashimoto, M.; Takeda, A.; Sagara, Y.; Sisk, A.; Mucke, L. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287(5456):1265-1269; 2000.
96. Mbefo, M. K.; Paleologou, K. E.; Boucharaba, A.; Oueslati, A.; Schell, H.; Fournier, M.; Olschewski, D.; Yin, G.; Zweckstetter, M.; Masliah, E.; Kahle, P. J.; Hirling, H.; Lashuel, H. A. Phosphorylation of synucleins by members of the Polo-like kinase family. J. Biol. Chem. 285(4):2807-2822; 2010.
97. McLaughlin, D.; Tsirimonaki, E.; Vallianatos, G.; Sakellaridis, N.; Chatzistamatiou, T.; Stavropoulos-Gioka, C.; Tsezou, A.; Messinis, I.; Mangoura, D. Stable expression of a neuronal dopaminergic progenitor phenotype in cell lines derived from human amniotic fluid cells. J. Neurosci. Res. 83(7):1190-1200; 2006.
98. Mills, R. D.; Sim, C. H.; Mok, S. S.; Mulhern, T. D.; Culvenor, J. G.; Cheng, H. C. Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1). J. Neurochem. 105(1):18-33; 2008.
99. Mitsumoto, A.; Nakagawa, Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic. Res. 35(6):885-893; 2001.
100. Mizuno, Y.; Hattori, N.; Kitada, T.; Matsumine, H.; Mori, H.; Shimura, H.; Kubo, S.; Kobayashi, H.; Asakawa, S.; Minoshima, S.; Shimizu, N. Familial Parkinson's disease. α-Synuclein and parkin. Adv. Neurol. 86:13-21; 2001.
101. Morgan, N. V.; Westaway, S. K.; Morton, J. E.; Gregory, A.; Gissen, P.; Sonek, S.; Cangul, H.; Coryell, J.; Canham, N.; Nardocci, N.; Zorzi, G.; Pasha, S.; Rodriguez, D.; Desguerre, I.; Mubaidin, A.; Bertini, E.; Trembath, R. C.; Simonati, A.; Schanen, C.; Johnson, C. A.; Levinson, B.; Woods, C. G.; Wilmot, B.; Kramer, P.; Gitschier, J.; Maher, E. R.; Hayflick, S. J. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat. Genet. 38(7):752-754; 2006.
102. Mueller, D.; Shamblott, M. J.; Fox, H. E.; Gearhart, J. D.; Martin, L. J. Transplanted human embryonic germ cell-derived neural stem cells replace neurons and oligodendrocytes in the forebrain of neonatal mice with excitotoxic brain damage. J. Neurosci. Res. 82(5):592-608; 2005.
103. Najim al-Din, A. S.; Wriekat, A.; Mubaidin, A.; Dasouki, M.; Hiari, M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol. Scand. 89(5):347-352; 1994.
104. Nemani, V. M.; Lu, W.; Berge, V.; Nakamura, K.; Onoa, B.; Lee, M. K.; Chaudhry, F. A.; Nicoll, R. A.; Edwards, R. H. Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66-79; 2010.
105. Nishioka, K.; Ross, O. A.; Vilarino-Guell, C.; Cobb, S. A.; Kachergus, J. M.; Mann, D. M.; Snowden, J.; Richardson, A. M.; Neary, D.; Robinson, C. A.; Rajput, A.; Papapetropoulos, S.; Mash, D. C.; Pahwa, R.; Lyons, K. E.; Wszolek, Z. K.; Dickson, D. W.; Farrer, M. J. Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism. Relat. Disord. 17(1):55-57; 2011.
106. Offen, D.; Sherki, Y.; Melamed, E.; Fridkin, M.; Brenneman, D. E.; Gozes, I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection in Parkinson's disease. Brain Res. 854(1-2):257-262; 2000.
107. Okabe, S.; Forsberg-Nilsson, K.; Spiro, A. C.; Segal, M.; McKay, R. D. Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. Mech. Dev. 59(1):89-102; 1996.
108. Okochi, M.; Walter, J.; Koyama, A.; Nakajo, S.; Baba, M.; Iwatsubo, T.; Meijer, L.; Kahle, P. J.; Haass, C. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J. Biol. Chem. 275(1):390-397; 2000.
109. Orth, M.; Tabrizi, S. J.; Tomlinson, C.; Messmer, K.; Korlipara, L. V.; Schapira, A. H.; Cooper, J. M. G209A mutant α-synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem. Int. 45(5):669-676; 2004.
110. Outeiro, T. F.; Kontopoulos, E.; Altmann, S. M.; Kufareva, I.; Strathearn, K. E.; Amore, A. M.; Volk, C. B.; Maxwell, M. M.; Rochet, J. C.; McLean, P. J.; Young, A. B.; Abagyan, R.; Feany, M. B.; Hyman, B. T.; Kazantsev, A. G. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837):516-519; 2007.
111. Ozelius, L. J.; Senthil, G.; Saunders-Pullman, R.; Ohmann, E.; Deligtisch, A.; Tagliati, M.; Hunt, A. L.; Klein, C.; Henick, B.; Hailpern, S. M.; Lipton, R. B.; Soto-Valencia, J.; Risch, N.; Bressman, S. B. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354(4):424-425; 2006.
112. Pankratz, N.; Pauciulo, M. W.; Elsaesser, V. E.; Marek, D. K.; Halter, C. A.; Wojcieszek, J.; Rudolph, A.; Shults, C. W.; Foroud, T.; Nichols, W. C. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci. Lett. 408(3):209-213; 2006.
113. Papka, M.; Rubio, A.; Schiffer, R. B. A review of Lewy body disease, an emerging concept of cortical dementia. J. Neuropsychiatry Clin. Neurosci. 10(3):267-279; 1998.
114. Park, H. J.; Lee, P. H.; Bang, O. Y.; Lee, G.; Ahn, Y. H. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J. Neurochem. 107(1):141-151; 2008.
115. Park, J.; Lee, S. B.; Lee, S.; Kim, Y.; Song, S.; Kim, S.; Bae, E.; Kim, J.; Shong, M.; Kim, J. M.; Chung, J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441(7097):1157-1161; 2006.
116. Periquet, M.; Fulga, T.; Myllykangas, L.; Schlossmacher, M. G.; Feany, M. B. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 27(12): 3338-3346; 2007.
117. Perlow, M. J.; Freed, W. J.; Hoffer, B. J.; Seiger, A.; Olson, L.; Wyatt, R. J. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204(4393):643-647; 1979.
118. Piccini, P.; Brooks, D. J.; Bjorklund, A.; Gunn, R. N.; Grasby, P. M.; Rimoldi, O.; Brundin, P.; Hagell, P.; Rehncrona, S.; Widner, H.; Lindvall, O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2(12):1137-1140; 1999.
119. Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E. S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W. G.; Lazzarini, A. M.; Duvoisin, R. C.; Di Iorio, G.; Golbe, L. I.; Nussbaum, R. L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047; 1997.
120. Poole, A. C.; Thomas, R. E.; Andrews, L. A.; McBride, H. M.; Whitworth, A. J.; Pallanck, L. J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. USA 105(5):1638-1643; 2008.
121. Pridgeon, J. W.; Olzmann, J. A.; Chin, L. S.; Li, L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5(7):e172; 2007.
122. Priyadarshi, A.; Khuder, S. A.; Schaub, E. A.; Priyadarshi, S. S. Environmental risk factors and Parkinson's disease: A meta-analysis. Environ. Res. 86(2):122-127; 2001.
123. Pronin, A. N.; Morris, A. J.; Surguchov, A.; Benovic, J. L. Synucleins are a novel class of substrates for G proteincoupled receptor kinases. J. Biol. Chem. 275(34):26515-26522; 2000.
124. Qing, H.; Wong, W.; McGeer, E. G.; McGeer, P. L. Lrrk2 phosphorylates a synuclein at serine 129: Parkinson disease implications. Biochem. Biophys. Res. Commun. 387(1):149-152; 2009.
125. Ramirez, A.; Heimbach, A.; Grundemann, J.; Stiller, B.; Hampshire, D.; Cid, L. P.; Goebel, I.; Mubaidin, A. F.; Wriekat, A. L.; Roeper, J.; Al-Din, A.; Hillmer, A. M.; Karsak, M.; Liss, B.; Woods, C. G.; Behrens, M. I.; Kubisch, C. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38(10):1184-1191; 2006.
126. Rodriguez-Oroz, M. C.; Jahanshahi, M.; Krack, P.; Litvan, I.; Macias, R.; Bezard, E.; Obeso, J. A. Initial clinical manifestations of Parkinson's disease: Features and pathophysiological mechanisms. Lancet Neurol. 8(12):1128-1139; 2009.
127. Rosenblad, C. Growth factor treatment of neurodegenerative disorders: New developments pave the way for clinical success. IDrugs 7(3):243-248; 2004.
128. Rossler, R.; Boddeke, E.; Copray, S. Differentiation of non-mesencephalic neural stem cells towards dopaminergic neurons. Neuroscience 170(2):417-428; 2010.
129. Roy, N. S.; Cleren, C.; Singh, S. K.; Yang, L.; Beal, M. F.; Goldman, S. A. Functional engraftment of human ES cellderived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 12(11):1259-1268; 2006.
130. Samii, A.; Nutt, J. G.; Ransom, B. R. Parkinson's disease. Lancet 363(9423):1783-1793; 2004.
131. Sherer, T. B.; Betarbet, R.; Greenamyre, J. T. Pesticides and Parkinson's disease. ScientificWorldJournal 1:207-208; 2001.
132. Sherer, T. B.; Betarbet, R.; Stout, A. K.; Lund, S.; Baptista, M.; Panov, A. V.; Cookson, M. R.; Greenamyre, J. T. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J Neurosci. 22(16):7006-7015; 2002.
133. Shimura, H.; Hattori, N.; Kubo, S.; Mizuno, Y.; Asakawa, S.; Minoshima, S.; Shimizu, N.; Iwai, K.; Chiba, T.; Tanaka, K.; Suzuki, T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25(3):302-305; 2000.
134. Shin, E. C.; Cho, S. E.; Lee, D. K.; Hur, M. W.; Paik, S. R.; Park, J. H.; Kim, J. Expression patterns of α-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. Mol. Cells 10(1):65-70; 2000.
135. Shojaee, S.; Sina, F.; Banihosseini, S. S.; Kazemi, M. H.; Kalhor, R.; Shahidi, G. A.; Fakhrai-Rad, H.; Ronaghi, M.; Elahi, E. Genome-wide linkage analysis of a Parkinsonianpyramidal syndrome pedigree by 500 K SNP arrays. Am. J. Hum. Genet. 82(6):1375-1384; 2008.
136. Smith, W. W.; Liu, Z.; Liang, Y.; Masuda, N.; Swing, D. A.; Jenkins, N. A.; Copeland, N. G.; Troncoso, J. C.; Pletnikov, M.; Dawson, T. M.; Martin, L. J.; Moran, T. H.; Lee, M. K.; Borchelt, D. R.; Ross, C. A. Synphilin-1 attenuates neuronal degeneration in the A53T α-synuclein transgenic mouse model. Hum. Mol. Genet. 19(11):2087-2098; 2010.
137. Soldner, F.; Hockemeyer, D.; Beard, C.; Gao, Q.; Bell, G. W.; Cook, E. G.; Hargus, G.; Blak, A.; Cooper, O.; Mitalipova, M.; Isacson, O.; Jaenisch, R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5):964-977; 2009.
138. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. α-Synuclein in Lewy bodies. Nature 388(6645):839-840; 1997.
139. Svendsen, C. N.; Caldwell, M. A.; Shen, J.; ter Borg, M. G.; Rosser, A. E.; Tyers, P.; Karmiol, S.; Dunnett, S. B. Longterm survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp. Neurol. 148(1):135-146; 1997.
140. Svendsen, C. N.; ter Borg, M. G.; Armstrong, R. J.; Rosser, A. E.; Chandran, S.; Ostenfeld, T.; Caldwell, M. A. A new method for the rapid and long term growth of human neural precursor cells. J. Neurosci. Methods 85(2):141-152; 1998.
141. Takahashi, M.; Yamada, T. Viral etiology for Parkinson's disease-a possible role of influenza A virus infection. Jpn. J. Infect. Dis. 52(3):89-98; 1999.
142. Takahashi, R.; Imai, Y.; Hattori, N.; Mizuno, Y. Parkin and endoplasmic reticulum stress. Ann. N. Y. Acad. Sci. 991:101-106; 2003.
143. Tan, E. K.; Ho, P.; Tan, L.; Prakash, K. M.; Zhao, Y. PLA2G6 mutations and Parkinson's disease. Ann. Neurol. 67(1):148; 2010.
144. Tanner, C. M. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv. Neurol. 91:133-142; 2003.
145. Thomas, B.; Beal, M. F. Parkinson's disease. Hum. Mol. Genet. 16 (Spec No. 2):R183-R194; 2007.
146. Tsai, M. S.; Hwang, S. M.; Tsai, Y. L.; Cheng, F. C.; Lee, J. L.; Chang, Y. J. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol. Reprod. 74(3):545-551; 2006.
147. Valente, E. M.; Abou-Sleiman, P. M.; Caputo, V.; Muqit, M. M.; Harvey, K.; Gispert, S.; Ali, Z.; Del Turco, D.; Bentivoglio, A. R.; Healy, D. G.; Albanese, A.; Nussbaum, R.; Gonzalez-Maldonado, R.; Deller, T.; Salvi, S.; Cortelli, P.; Gilks, W. P.; Latchman, D. S.; Harvey, R. J.; Dallapiccola, B.; Auburger, G.; Wood, N. W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304(5674):1158-1160; 2004.
148. Van Den Eeden, S. K.; Tanner, C. M.; Bernstein, A. L.; Fross, R. D.; Leimpeter, A.; Bloch, D. A.; Nelson, L. M. Incidence of Parkinson's disease: Variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157(11):1015-1022; 2003.
149. Vater, C.; Kasten, P.; Stiehler, M. Culture media for the differentiation of mesenchymal stromal cells. Acta Biomater. 7(2):463-477; 2011.
150. Vercueil, L.; Pollak, P.; Fraix, V.; Caputo, E.; Moro, E.; Benazzouz, A.; Xie, J.; Koudsie, A.; Benabid, A. L. Deep brain stimulation in the treatment of severe dystonia. J. Neurol. 248(8):695-700; 2001.
151. Videnovic, A.; Metman, L. V. Deep brain stimulation for Parkinson's disease: Prevalence of adverse events and need for standardized reporting. Mov. Disord. 23(3):343-349; 2008.
152. Vierbuchen, T.; Ostermeier, A.; Pang, Z. P.; Kokubu, Y.; Sudhof, T. C.; Wernig, M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463(7284):1035-1041; 2010.
153. Wakabayashi, K.; Engelender, S.; Tanaka, Y.; Yoshimoto, M.; Mori, F.; Tsuji, S.; Ross, C. A.; Takahashi, H. Immunocytochemical localization of synphilin-1, an α-synucleinassociated protein, in neurodegenerative disorders. Acta Neuropathol. 103(3):209-214; 2002.
154. Wakabayashi, K.; Engelender, S.; Yoshimoto, M.; Tsuji, S.; Ross, C. A.; Takahashi, H. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47(4):521-523; 2000.
155. Wakeman, D. R.; Dodiya, H. B.; Kordower, J. H. Cell transplantation and gene therapy in Parkinson's disease. Mt. Sinai J. Med. 78(1):126-158; 2011.
156. Wang, L.; Guo, J. F.; Zhang, W. W.; Xu, Q.; Zuo, X.; Shi, C. H.; Luo, L. Z.; Liu, J.; Hu, L.; Hu, Y. C.; She, L.; Jiang, H.; Yan, X. X.; Xia, K.; Pan, Q.; Tang, B. S. Novel GIGYF2 gene variants in patients with Parkinson's disease in Chinese population. Neurosci. Lett. 473(2):131-135; 2010.
157. Waxman, E. A.; Giasson, B. I. Specificity and regulation of casein kinase-mediated phosphorylation of α-synuclein. J. Neuropathol. Exp. Neurol. 67(5):402-416; 2008.
158. Williams, A. E.; Arzola, G. M.; Strutt, A. M.; Simpson, R.; Jankovic, J.; York, M. K. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 17(5):321-327; 2011.
159. Xiong, N.; Zhang, Z.; Huang, J.; Chen, C.; Zhang, Z.; Jia, M.; Xiong, J.; Liu, X.; Wang, F.; Cao, X.; Liang, Z.; Sun, S.; Lin, Z.; Wang, T. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 18(4):394-402; 2010.
160. Yasuda, T.; Nihira, T.; Ren, Y. R.; Cao, X. Q.; Wada, K.; Setsuie, R.; Kabuta, T.; Wada, K.; Hattori, N.; Mizuno, Y.; Mochizuki, H. Effects of UCH-L1 on α-synuclein overexpression mouse model of Parkinson's disease. J. Neurochem. 108(4):932-944; 2009.
161. Ye, W.; Shimamura, K.; Rubenstein, J. L.; Hynes, M. A.; Rosenthal, A. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 93(5):755-766; 1998.
162. Yokota, T.; Sugawara, K.; Ito, K.; Takahashi, R.; Ariga, H.; Mizusawa, H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem. Biophys. Res. Commun. 312(4):1342-1348; 2003.
163. Yoshino, H.; Tomiyama, H.; Tachibana, N.; Ogaki, K.; Li, Y.; Funayama, M.; Hashimoto, T.; Takashima, S.; Hattori, N. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 75(15):1356-1361; 2010.
164. Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; Antosiewicz- Bourget, J.; Frane, J. L.; Tian, S.; Nie, J.; Jonsdottir, G. A.; Ruotti, V.; Stewart, R.; Slukvin, I. I.; Thomson, J. A. Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917-1920; 2007.
165. Zhang, L.; Shimoji, M.; Thomas, B.; Moore, D. J.; Yu, S. W.; Marupudi, N. I.; Torp, R.; Torgner, I. A.; Ottersen, O. P.; Dawson, T. M.; Dawson, V. L. Mitochondrial localization of the Parkinson's disease related protein DJ-1: Implications for pathogenesis. Hum. Mol. Genet. 14(14):2063-2073; 2005.
166. Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R. J.; Calne, D. B.; Stoessl, A. J.; Pfeiffer, R. F.; Patenge, N.; Carbajal, I. C.; Vieregge, P.; Asmus, F.; Muller-Myhsok, B.; Dickson, D. W.; Meitinger, T.; Strom, T. M.; Wszolek, Z. K.; Gasser, T. Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 44(4):601-607; 2004.